

Assets

1. Test to detect predisposition to suicide.
2. Nutraceuticals demonstrated to reduce biochemicals causative of suicide
3. Nine patents covering completely new means of addressing suicide and predisposing conditions

Team

Kalina O'Connor, President and CEO. Serial entrepreneur, suicide prevention advocate

Timothy Dixon, Board Member and CEO of founding company Therapeutics Solutions International. Multiple successes in private and public companies.

Dr. James Veltmeyer, Chief Medical Officer. Inventor, entrepreneur and key opinion leader. Voted Top Doctor of San Diego.

Thomas Ichim, PhD, Founding Scientist. Numerous private and public company exits. 150 patents and patent applications. 124 peer reviewed papers.

Jona Barnes, CPA, Chief Financial Officer. Over 30 years experience in private and public companies.

Offering

We are currently selling shares at \$0.25 cents per share, total shares available for purchase are 10,000,000 giving the Company a current worth of \$9.375 million.

The Company is raising a total of \$2,500,000

Comparator Deals

1. Novartis purchase of Cadent, \$770 million deal for Phase 1 schizophrenia candidates
2. Cypress Bioscience and Forest Laboratories \$200 million for collaboration on preclinical drug candidate for fibromyalgia
3. Neurocrine licensing of Voyager's CNS Phase I candidate \$1.8 billion



Campbell Neurosciences, Inc.

Discover the future...

Treating Suicide as a Disease

Campbell Neurosciences is based on leveraging the fact that the second leading cause of death in young people, suicide, is not currently being treated as a disease.

The stigma associated with suicide, as well as contributing factors such as schizophrenia, has inhibited "cure-based" research. Instead, "band aid" solutions which are synthetic versions of mind-altering drugs are being pumped into patients, generating billions for pharmaceutical companies, while only temporarily helping a subset of victims. The Company has developed the first blood-based marker for suicidal propensity, the Campbell Score™, as well as accumulated patents and data on treatments addressing the cause of mental illnesses causing suicide: neuroinflammation.

Campbell Score™

Psychiatry, despite commanding a \$240 billion a year market, is the only branch of medicine that does not directly quantify efficacy of its interventions to its target organ. The Campbell Score™ provides an objective tool for psychiatrists to know how well their interventions are working before the patient begins to experience psychological manifestations. By detecting brain inflammation, it is a "stethoscope" for determining severity of mental illnesses associated with increased suicide risk such as schizophrenia, PTSD, and opioid addiction.

Regenerative Psychiatry: Schizophrenia Lead

Mental illnesses associated with suicide, such as schizophrenia, are characterized by inflammation and a reduced ability of stem cells in the brain to function. Patients with schizophrenia have 170 times higher suicide rates as compared to non-schizophrenics. The Company is focused on utilizing its "regenerative psychiatry" approach to reduce inflammation and restore the ability of brain cells to repair themselves in advanced schizophrenic patients resistant to treatment. Success in this area will allow for expansion into PTSD and opioid addiction, which predispose to suicide and possess similar biological characteristics.

Path to Success Plan

1. **Intellectual property dominance of immunology and regenerative medicine space as relates to suicide:** Identifying who owns what and filing patents to cover anything related to suicide and predisposing factors (completed).
2. **Sales of Campbell Score™ and TSOI nutraceuticals** to psychiatrists paid by "out of pocket" (Q2 2021)
3. **FDA registration of Campbell Score™.** Requires 200 patient trial, will provide ability to generate revenue or partnership (Q1 2022).
4. **Success of "Regenerative Psychiatry" approach in treatment resistant schizophrenics.** Using proprietary microbiome modulation, nutraceutical, and stem cells. Success in patients whose only option is electroconvulsive therapy will be a paradigm shift in the industry (Q1 2022).
5. **Acquisition/IPO.** Based on patents, method of diagnosis and pipeline (Q2 2022) \$200 million-1.8 billion are comparator deals.